UBC Physics & Astronomy Department Colloquium on July 16, 2020. Presented by Andrew Robertson (UBC).
phas.ubc.ca/225-actinium-prod...
225Ac is an alpha-emitting radionuclide that has shown remarkable potential for use in targeted alpha therapy of late stage metastatic diseases, most notably prostate cancer. However, 225Ac-radiopharmaceutical development remains limited by the insufficient availability of the radionuclide, despite multiple efforts to increase 225Ac supply via alternative methods that avoid the use of nuclear weapons material. Accelerator-based methods are a potential alternative, with TRIUMF’s 500-MeV cyclotron uniquely positioned to produce substantial quantities of 225Ac via thorium irradiation that do not contain undesirable 227Ac impurities. In this talk I will discuss TRIUMF’s ongoing efforts to produce 225Ac, with a focus on the current state of the technology and the physical science foundation behind it. This foundation combines topics from multiple disciplines, but will be presented from the perspective of a physicist (who by accident now does a lot of chemistry). Topics include the design and modelling of thorium proton-targets, nuclear reaction cross-section measurements, high-energy particle transport simulations, chemical purification methods, and analytical techniques for determining product quality.
6 авг 2024
